Public Policy Letters, Statements, Legal Briefs, & Other Responses
-
ACMG Comments to Congress Concerning the Verifying Accurate Leading-edge IVCT Development (VALID) Act Discussion Draft
-
Group Sign-on Letter to CMS Requesting Revision of Interpretation of NCD for NGS for Advanced Cancer
-
Group Sign-on Letter to Congress (Senate) Requesting FY 2019 Appropriations for Newborn Screening Programs
-
Group Sign-on Letter to Congress (House) Requesting FY 2019 Appropriations for Newborn Screening Programs
-
ACMG Letter to Congress Concerning the FDA Technical Assistance for the Diagnostic Accuracy and Innovation Act (DAIA)
-
Group Sign-on Letter to Congress Concerning the Diagnostic Accuracy and Innovation Act (DAIA)
-
Group Sign-on Letter to Congress Requesting FY 2019 Appropriations for the National Institute of Child Health and Human Development (NICHD)
-
ACMG Responds to FDA’s Approval for DTC Testing for Three BRCA Gene Mutations
-
ACMG Comments to CMS on Proposed NCD for Coverage of NGS for Medicare Beneficiaries with Advanced Cancer (CAG-00450N)
-
Group Sign-on Letter to Congress (Senate) Opposing President’s Proposal to Eliminate Funding for HRSA’s Heritable Disorders Program